Research programme: HMG CoA reductase inhibitors controlled release - Oxford Pharmascience

Drug Profile

Research programme: HMG CoA reductase inhibitors controlled release - Oxford Pharmascience

Alternative Names: Atorvastatin - Oxford Pharmascience; OXP 003; OXP 004; Safestat™ Atorvastatin; Safestat™ Simvastatin; Simvastatin - Oxford Pharmascience; Statins modified release - Oxford Pharmascience

Latest Information Update: 17 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oxford Pharmascience
  • Class Amides; Fluorobenzenes; Heptanoic acids; Naphthalenes; Pyrroles; Small molecules
  • Mechanism of Action HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cardiovascular disorders

Most Recent Events

  • 09 Nov 2016 Development of a new colon-targeted formulation of atorvastatin for cardiovascular disorders is ongoing in United Kingdom
  • 30 Apr 2014 Oxford Pharmascience plans a phase I trial of its atorvastatin product for Hyperlipidaemia in the United Kingdom
  • 17 Mar 2014 Research programme: HMG CoA reductase inhibitors controlled release - Oxford Pharmascience is available for licensing as of 17 Mar 2014. http://www.oxfordpharmascience.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top